Stay updated with breaking news from Rna. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) have earned an average recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have issued ratings on the […]
Abrdn plc acquired a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 129,414 shares of the biotechnology company’s stock, valued at approximately $1,171,000. Other hedge funds and other institutional investors also recently made changes to their positions in the company. Adage Capital […]
A recent study finds RNA deals are “dominated” by oligonucleotides and mRNA vaccines in APAC
Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) Director Arthur A. Levin sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, April 19th. The stock was sold at an average price of $22.82, for a total transaction of $114,100.00. Following the sale, the director now directly owns 14,830 shares in […]
Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) Director Arthur A. Levin sold 5,000 shares of the stock in a transaction that occurred on Friday, April 19th. The shares were sold at an average price of $22.82, for a total transaction of $114,100.00. Following the completion of the sale, the director now owns 14,830 shares […]